Biomet/Walter Lorenz TMJ Replacement PMA Set For Aug. 22 Panel Review
This article was originally published in The Gray Sheet
Executive Summary
FDA's Dental Products Advisory panel will review Biomet/Walter Lorenz Surgical's PMA for the TMJ total temporomandibular joint replacement system at an Aug. 22 meeting in Gaithersburg, Maryland
You may also be interested in...
Panel Recommends Conditional Approval of TMJ Implants' Prosthetic Device
TMJ Implants, Inc. should conduct a prospective, three to five-year study to gather long-term safety and efficacy data on a patient population classified according to interventional history and individual patient indication, FDA's Dental Products Panel concluded May 11 in Gaithersburg, Maryland.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.